4SC AG (VSC.F)

8.60 +0.36 (+4.37%) At close: 02:25PM CEST

4SC AG

Fraunhoferstraße 22
Planegg 82152
Germany
49 89 700 763 0
https://www.4sc.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 13

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jason Loveridge B.Sc., FRSM, Ph.D.	Chairman of Management Board, CEO & MD	519k	N/A	N/A
Ms. Kathleen Masch-Wiest	COO & Member of the Management Board	N/A	N/A	N/A
Ms. Anna Niedl Ph.D.	Corporate Communications & Investor Relations Officer	N/A	N/A	N/A
Dr. Susanne Danhauser-Riedl M.D.	Chief Medical Officer	N/A	N/A	N/A
Ms. Larissa Stuttem	Team Assistant	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany. Its product Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma, which is in clinical development stage. The company also out-licenses its products to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany.

Corporate governance

4SC AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.